Clinical trials: Clopidogrel, completed
Coronary Artery Disease
Clopidogrel Use and Long-term Safety After Drug-Eluting Stents Implantation
The purpose of ZEST-LATE (Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events)…
- Trial name
- ZEST-LATE (NCT00590174)
- Testing
- Aspirin, Aspirin,Clopidogrel
- Where
- 20 sites in South Korea
- Volunteers
- 1,175 people
- Sponsor
- Seung-Jung Park
Healthy
The Antiplatelet and Immune Response Trial
Platelets are the main type of blood cell involved in the formation of blood clots that cause heart attacks. The investigators give antiplatelet drugs (aspirin, for example) to reduce the risk of another clot forming in the…
- Trial name
- NCT01846559
- Testing
- Endotoxin, Clopidogrel, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Saphenous Vein Graft Atherosclerosis
Drug-Eluting Stents vs. Bare Metal Stents In Saphenous Vein Graft Angioplasty
Patients who have undergone coronary bypass surgery have had a vein removed from the leg and implanted in the chest to "bypass" blockages in the coronary arteries. These veins are called saphenous vein grafts or SVGs.
- Trial name
- DIVA (NCT01121224)
- Testing
- Bare Metal Stent, Drug-Eluting Stent, Blinded clopidogrel
- Where
- 25 sites in United States
- Volunteers
- 597 people
- Sponsor
- VA Office of Research and Development
Atherosclerosis
Trial of Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial)
The purpose of this study is to determine whether the combination of clopidogrel with aspirin prevents the development of blockages (atherosclerosis) in vein grafts one year after coronary artery bypass surgery (CABG) compared to…
- Trial name
- CASCADE (NCT00228423)
- Testing
- Clopidogrel 75 mg daily, water pill daily
- Where
- Canada
- Volunteers
- 113 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Healthy
Impact of a High-fat Meal on Assessment of Clopidogrel-induced Platelet Inhibition in Healthy Subjects
The purpose of this study is to determine whether a high-fat meal affects the ability of platelet function tests to measure platelet inhibition by clopidogrel.
- Trial name
- NCT01307657
- Testing
- high fat meal
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Coronary Artery Disease (CAD)
Prasugrel Versus High Dose Clopidogrel in Patients With Stable Coronary Artery Disease and High Platelet Reactivity While on Chronic Clopidogrel Treatment
Clopidogrel administration is considered standard of care in patients with stable coronary artery disease post PCI. However , a significant proportion of patients is considered clopidogrel resistant and this is shown to be…
- Trial name
- NCT01304472
- Testing
- Prasugrel, Clopidogrel
- Where
- 2 sites in Greece
- Volunteers
- 25 people
- Sponsor
- University of Patras
Non-ST or ST Elevation Acute Coronary Syndromes
A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS
The purpose of this study is to test the hypothesis that the onset of the antiplatelet effect of ticagrelor is more rapid and greater than clopidogrel in Chinese patients with ACS.
- Trial name
- HouYi (NCT01864005)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Cerebral Infarction, Atherosclerosis
Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
This study will recruit 480 acute stroke patients with symptomatic intracranial stenosis (M1 segment of Middle cerebral artery (MCA) or basilar artery). They will be randomly assigned into cilostazol group or clopidogrel group.
- Trial name
- TOSS-2 (NCT00130039)
- Testing
- clopidogrel, Cilostazol
- Where
- 19 sites in Hong Kong, Philippines and 2 more
- Volunteers
- 457 people
- Sponsor
- Asan Medical Center
Acute Coronary Syndromes
Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes
For octogenarian patients with NSTEMI (non-ST segment elevation myocardial infarction) an invasive-guided strategy will prove superior to a conservative strategy with respect to a combined endpoint of all cause mortality and…
- Trial name
- RINCAL (NCT02086019)
- Testing
- Conservative Arm, Invasive Arm
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Brighton and Sussex University Hospitals NHS Trust
Ischemic Stroke
Clopidogrel Versus Cilostazol in Large-vessel Ischemic Stroke
Along with the current clinical trial, the efficacy and safety of a 300 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel ischemic stroke compared to 200 mg cilostazol were assessed through…
- Trial name
- NCT06242145
- Testing
- Clopidogrel tablet, Cilostazol 100 MG
- Where
- Egypt
- Volunteers
- 580 people
- Sponsor
- Kafrelsheikh University
Type 2 Diabetes Mellitus, Coronary Artery Disease
Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)
Patients with diabetes are more likely to develop furring of their coronary arteries and present with angina and heart attacks. Furthermore, after such an event, they have poorer outcomes (higher rates of death) and survivors are…
- Trial name
- NCT00728156
- Testing
- clopidogrel
- Where
- 2 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Acute ST Segment Elevation Myocardial Infarction, Thrombolysis in Myocardial Infarction Flow
Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis
Administration of Ticagrelor in patients with ST elevation myocardial infarction treated with pharmacological thrombolysis
- Trial name
- TREAT (NCT02298088)
- Testing
- Ticagrelor 180 mg, Clopidogrel
- Where
- 153 sites in Argentina, Australia and 8 more
- Volunteers
- 3,799 people
- Sponsor
- Hospital do Coracao
Coronary Artery Disease, Acute Coronary Syndrome
Ticagrelor Versus Prasugrel in Acute Coronary Syndromes After Percutaneous Coronary Intervention
This is a single-center, randomized, single-blind, investigator-initiated pharmacological study with a crossover design. Patients with acute coronary syndrome (ST-elevation myocardial infarction, non-ST elevation myocardial…
- Trial name
- NCT01360437
- Testing
- Prasugrel, Ticagrelor
- Where
- Greece
- Volunteers
- 44 people
- Sponsor
- University of Patras
Drug-Interactions
Effect of Fluvastatin on Top of Clopidogrel and Aspirin in Patients After DES Implantation on Platelet Aggregation
The purpose of the study was to determine the influence of fluvastatin and atorvastatin on platelet aggregation in patients treated with aspirin and plavix after coronary stenting.
- Trial name
- EFA-1 (NCT00465322)
- Testing
- fluvastatin
- Where
- Switzerland
- Volunteers
- 100 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Myocardial Ischemia, CLOPIDOGREL, POOR METABOLISM of (Disorder)
Genotyping Influences Outcome of Coronary Artery Stenting
This study evaluated epidemiology and clinical outcome of clopidogrel related various genotyping in Korean patients who had undergone percutaneous coronary intervention as a all comer registry form.
- Trial name
- GENIUS (NCT02707445)
- Testing
- Clopidogrel
- Volunteers
- 5,000 people
- Sponsor
- Korea University Anam Hospital
STEMI
Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
The objective of the RAPID STEMI study is to evaluate the feasibility, efficacy, and safety of a pharmacogenetic approach to anti-platelet therapy for the treatment of ST-segment elevation myocardial infarction (STEMI) patients…
- Trial name
- RAPID STEMI (NCT01452139)
- Testing
- Point-of-Care Genetic Testing, Prasugrel
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Ischemic Stroke, Mild
ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)
The purpose of this study is to investigate the safety and efficacy of rhPro-UK (35mg) versus standard medical treatment in acute mild ischemic stroke within 4.5 hours of symptom onset.
- Conditions
- Ischemic Stroke, Mild, Thrombosis
- Trial name
- PUMICE (NCT05507645)
- Testing
- Recombinant Human Prourokinase for Injection (rhPro-UK), standard medical treatment
- Where
- 89 sites in China
- Volunteers
- 1,446 people
- Sponsor
- Beijing Tiantan Hospital
Bioequivalence
Bioequivalence Study of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® 75 mg Tablet After Oral Administration to Healthy Adult Subjects Under Fasting Condition
To compare the rate and extent of absorption of Clopid® (Clopidogrel) 75 mg Tablet and Plavix® (clopidogrel) 75 mg tablet under fasting condition.
- Trial name
- NCT05186129
- Testing
- Clopid® 75 mg Tablet, Plavix® 75mg Tablet
- Where
- Pakistan
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Center for Bioequivalence Studies and Clinical Research
Healthy
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects
To test pharmacodynamic response to clopidogrel 150mg once daily during 7 days in healthy subjects carriers of a mutated allele (*2) associated with CYP2C19 deficiency and non responders to the usual regimen of 75 mg once daily
- Trial name
- NCT00413608
- Testing
- Clopidogrel
- Where
- France
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Healthy
Fasting Study of Clopidogrel Bisulfate Tablets 75 mg to Plavix® Tablets 75 mg
The objective of this study was to investigate the bioequivalence of Mylan's clopidogrel bisulfate 75 mg tablets to Bristol-Myers Squibb/Sanofi's Plavix® 75 mg tablets following a single, oral 75 mg (1 x 75 mg) dose administered…
- Trial name
- NCT00648947
- Testing
- Clopidogrel Bisulfate Tablets 75 mg, Plavix® Tablets 75 mg
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc